ImmunoPrecise Reports Record Revenues and Positive Adjusted EBITDA Fiscal 2020
- Monday, August 31, 2020, 6:44
- Finance
- Add a comment
Reports rapid advancement of COVID-19 antibody programs; combination studies achieve nearly complete neutralization of SARS-CoV-2 VICTORIA, BC, Aug. 31, 2020 /PRNewswire/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) today announced financial results…
About the Author
adminasapcorp has written 38938 stories on this site.